BMS Opts In On Exscientia’s AI-Designed Immune-Modulating Candidate
Bristol Myers Squibb Will Handle Compound’s Clinical, Commercial Development
• By Sten Stovall
AI-designed drug is first in duo's multi-target collaboration to reach in-license milestone • Source: Alamy 
